Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06627816
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-03
Brief Title:
Efficacy of Intravenous Nefopam Dexmedetomidine and Meperidine in Preventing Post-Spinal Anesthesia Shivering in Adult Patients Undergoing Lower Abdominal and Lower Limb Surgeries
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Efficacy of Intravenous Nefopam Dexmedetomidine and Meperidine in Preventing Post-Spinal Anesthesia Shivering in Adult Patients Undergoing Lower Abdominal and Lower Limb Surgeries A Double-Blind Comparative Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This prospective randomized controlled double-blinded study is designed to evaluate the efficacy of nefopam compared to dexmedetomidine and meperidine for the prevention of postspinal anesthesia shivering while minimizing side effects
Detailed Description:
Numerous clinical studies have demonstrated that nefopam effectively prevents and treats postoperative shivering after general anesthesia For instance a dose of 015 mgkg nefopam is comparable in efficacy to 05 µgkg dexmedetomidine for treating shivering after orthopedic or abdominal surgery Additionally 20 mg of nefopam is equally effective as 50 mg of meperidine in preventing shivering following certain neurosurgical procedures Notably patients administered nefopam experience less sedation and hypotension compared to those given dexmedetomidine However further research is needed to evaluate nefopams effects on preventing shivering after neuraxial blockades
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None